News
In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...
In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback